Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 7,000 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider David M. Chao sold 7,000 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $17.17, for a total value of $120,190.00. Following the completion of the sale, the insider now directly owns 225,007 shares of the company’s stock, valued at approximately $3,863,370.19. This represents a 3.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Centessa Pharmaceuticals Stock Performance

CNTA stock opened at $15.75 on Friday. Centessa Pharmaceuticals plc has a 1 year low of $7.75 and a 1 year high of $19.09. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -10.29 and a beta of 1.54. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The stock’s fifty day moving average is $16.47 and its two-hundred day moving average is $16.38.

Institutional Trading of Centessa Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in Centessa Pharmaceuticals by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock worth $959,000 after purchasing an additional 660 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after buying an additional 865 shares during the period. Atria Investments Inc grew its holdings in Centessa Pharmaceuticals by 7.0% in the 3rd quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock worth $274,000 after buying an additional 1,116 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Centessa Pharmaceuticals in the 4th quarter valued at approximately $31,000. Finally, Barclays PLC raised its stake in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after acquiring an additional 4,952 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CNTA. Morgan Stanley reiterated an “overweight” rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating on the stock. Finally, Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $26.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.